Disc Medicine, Inc. (NASDAQ:IRON) Receives $104.80 Consensus Price Target from Brokerages

Disc Medicine, Inc. (NASDAQ:IRON) has received a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and ten have given a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $104.80.

IRON has been the subject of several analyst reports. TD Cowen restated a “buy” rating on shares of Disc Medicine in a report on Friday, December 19th. UBS Group reiterated an “overweight” rating on shares of Disc Medicine in a research note on Thursday, January 15th. Wedbush reduced their price objective on shares of Disc Medicine from $110.00 to $88.00 and set an “outperform” rating for the company in a research note on Tuesday, February 17th. Stifel Nicolaus decreased their target price on shares of Disc Medicine from $125.00 to $110.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Finally, Cantor Fitzgerald dropped their target price on shares of Disc Medicine from $153.00 to $125.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 17th.

Insider Buying and Selling

In related news, Director Kevin Bitterman sold 68,923 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $91.24, for a total value of $6,288,534.52. Following the transaction, the director directly owned 14,161 shares of the company’s stock, valued at approximately $1,292,049.64. This represents a 82.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Rahul Khara sold 6,500 shares of Disc Medicine stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $78.69, for a total value of $511,485.00. Following the completion of the sale, the insider directly owned 37,793 shares of the company’s stock, valued at approximately $2,973,931.17. The trade was a 14.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 292,492 shares of company stock worth $25,423,925 over the last 90 days. 3.64% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Disc Medicine

Several large investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Disc Medicine by 22.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company’s stock worth $756,000 after buying an additional 2,807 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Disc Medicine by 1,277.1% during the 1st quarter. Millennium Management LLC now owns 108,499 shares of the company’s stock valued at $5,386,000 after acquiring an additional 100,620 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Disc Medicine by 3.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company’s stock worth $4,793,000 after acquiring an additional 3,454 shares during the period. CWM LLC raised its holdings in shares of Disc Medicine by 213.5% during the second quarter. CWM LLC now owns 1,044 shares of the company’s stock valued at $55,000 after purchasing an additional 711 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Disc Medicine during the second quarter valued at approximately $497,000. 83.70% of the stock is currently owned by institutional investors.

Disc Medicine Price Performance

IRON stock opened at $61.18 on Thursday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 23.45 and a current ratio of 21.94. The firm has a 50 day moving average price of $72.69 and a 200-day moving average price of $75.62. Disc Medicine has a 52-week low of $30.82 and a 52-week high of $99.50. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of -10.21 and a beta of 0.87.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($1.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.69) by $0.07. The company had revenue of ($19.88) million for the quarter, compared to analysts’ expectations of $0.15 million. Equities research analysts forecast that Disc Medicine will post -4.07 EPS for the current fiscal year.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.